<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Satellos Bioscience Inc. — News on 6ix</title>
<link>https://6ix.com/company/satellos-bioscience-inc</link>
<description>Latest news and press releases for Satellos Bioscience Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/satellos-bioscience-inc" rel="self" type="application/rss+xml" />
<item>
<title>Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-to-present-at-the-bloom-burton-and-co-healthcare-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-to-present-at-the-bloom-burton-and-co-healthcare-investor-conference</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)&#...</description>
</item>
<item>
<title>Satellos Reports 2025 Financial Results and Highlights Recent Company Progress</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-reports-2025-financial-results-and-highlights-recent-company-progress</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-reports-2025-financial-results-and-highlights-recent-company-progress</guid>
<pubDate>Fri, 27 Mar 2026 11:00:00 GMT</pubDate>
<description>Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under...</description>
</item>
<item>
<title>Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-presents-interim-sat-3247-clinical-and-biomarker-data-in-duchenne-muscular-dystrophy-at-the-2026-mda-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-presents-interim-sat-3247-clinical-and-biomarker-data-in-duchenne-muscular-dystrophy-at-the-2026-mda-clinical-and-scientific-conference</guid>
<pubDate>Tue, 10 Mar 2026 11:00:00 GMT</pubDate>
<description>Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip stre...</description>
</item>
<item>
<title>Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-upcoming-oral-and-poster-presentations-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-upcoming-oral-and-poster-presentations-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO, February 24, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.</description>
</item>
<item>
<title>Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-to-host-virtual-kol-event-on-sat-3247-in-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-to-host-virtual-kol-event-on-sat-3247-in-duchenne-muscular-dystrophy</guid>
<pubDate>Wed, 18 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO, February 18, 2026--Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, Feb. 24, 2026, at 3:30 p.m. ET, featuring Kevin M. Flanigan, MD, the Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and professor of pediatrics a</description>
</item>
<item>
<title>Satellos to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-participate-upcoming-investor-conferences-120000271</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-participate-upcoming-investor-conferences-120000271</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO, February 17, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will present at and participate in the following investor conferences:</description>
</item>
<item>
<title>Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-first-participant-dosed-120000270</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-first-participant-dosed-120000270</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO, February 12, 2026--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy ("Duchenne" or "DMD").</description>
</item>
<item>
<title>Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-participate-guggenheim-securities-emerging-120000905</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-participate-guggenheim-securities-emerging-120000905</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO, February 10, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in NYC on Thursday, Feb. 12, 2026, at 10 a.m. ET.</description>
</item>
<item>
<title>Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-closes-us-57-2-220000126</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-closes-us-57-2-220000126</guid>
<pubDate>Mon, 09 Feb 2026 22:00:00 GMT</pubDate>
<description>TORONTO, February 09, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has completed its previously-announced underwritten public offering (the "Offering") of 5,168,019 common shares, which includes the exercise of the underwriters’ option to purchase an additional 712,574 common shares and, in lieu of common shares for c</description>
</item>
<item>
<title>Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-closes-usdollar572-million-public-offering-in-canada-and-the-united-states-including-exercise-of-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-closes-usdollar572-million-public-offering-in-canada-and-the-united-states-including-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Mon, 09 Feb 2026 22:00:00 GMT</pubDate>
<description>Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (&#x201C;Satellos&#x201D; or the &#x201C;Co...</description>
</item>
<item>
<title>Canadian Investment Regulatory Organization Trade Resumption - MSCL</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/canadian-investment-regulatory-organization-trade-resumption-mscl</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/canadian-investment-regulatory-organization-trade-resumption-mscl</guid>
<pubDate>Fri, 06 Feb 2026 13:59:00 GMT</pubDate>
<description>Canadian Investment Regulatory Organization Trade Resumption - MSCL Canada NewsWire ...</description>
</item>
<item>
<title>Canadian Investment Regulatory Organization Trading Halt - MSCL</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/canadian-investment-regulatory-organization-trading-halt-mscl</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/canadian-investment-regulatory-organization-trading-halt-mscl</guid>
<pubDate>Fri, 06 Feb 2026 13:48:00 GMT</pubDate>
<description>Canadian Investment Regulatory Organization Trading Halt - MSCL Canada NewsWire TO...</description>
</item>
<item>
<title>Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-pricing-us-50-133000784</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-pricing-us-50-133000784</guid>
<pubDate>Fri, 06 Feb 2026 13:30:00 GMT</pubDate>
<description>TORONTO, February 06, 2026--Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the "Offering") of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10</description>
</item>
<item>
<title>Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-launch-public-offering-212000625</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-launch-public-offering-212000625</guid>
<pubDate>Thu, 05 Feb 2026 21:20:00 GMT</pubDate>
<description>TORONTO, February 05, 2026--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the filing of a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated October 29, 2025 (the "Base Prospectus"), in connection with a proposed public offering of its common shares (or pre-funded warrants to purchase</description>
</item>
<item>
<title>Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-appoints-antoinette-paone-as-chief-development-officer-and-head-of-regulatory-affairs</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-appoints-antoinette-paone-as-chief-development-officer-and-head-of-regulatory-affairs</guid>
<pubDate>Thu, 29 Jan 2026 12:00:00 GMT</pubDate>
<description>Experienced industry leader brings extensive expertise in leading breakthrough therapies through ...</description>
</item>
<item>
<title>Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-share-consolidation-in-connection-with-proposed-nasdaq-listing</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-share-consolidation-in-connection-with-proposed-nasdaq-listing</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>Satellos Bioscience Inc . (TSX: MSCL, OTCQB: MSCLF) (&#x201C; Satellos &#x201D; or the &#x2...</description>
</item>
<item>
<title>Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-receives-clearance-by-us-fda-and-global-regulators-to-initiate-pediatric-phase-2-study-of-sat-3247-for-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-receives-clearance-by-us-fda-and-global-regulators-to-initiate-pediatric-phase-2-study-of-sat-3247-for-duchenne-muscular-dystrophy</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>- Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among amb...</description>
</item>
<item>
<title>Satellos to Participate in December Investor Conferences</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-to-participate-in-december-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-to-participate-in-december-investor-conferences</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (&#x201C;Satellos&#x201D; or the &#x201C;Compa...</description>
</item>
<item>
<title>Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-publication-in-nature-communications-supporting-its-novel-treatment-approach-for-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-announces-publication-in-nature-communications-supporting-its-novel-treatment-approach-for-duchenne-muscular-dystrophy</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogeni...</description>
</item>
<item>
<title>Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors</title>
<link>https://6ix.com/company/satellos-bioscience-inc/news/satellos-reports-third-quarter-2025-results-and-announces-appointment-of-mark-nawacki-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/satellos-bioscience-inc/news/satellos-reports-third-quarter-2025-results-and-announces-appointment-of-mark-nawacki-to-board-of-directors</guid>
<pubDate>Fri, 14 Nov 2025 12:00:00 GMT</pubDate>
<description>Appointed Mark Nawacki, seasoned M&amp;A expert, co-founder, president &amp; former CEO of Search...</description>
</item>
</channel>
</rss>